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Purpose: PCORnet, the National Patient‐Centered Clinical Research Network, rep-
resents an innovative system for the conduct of observational and pragmatic studies.
We describe the identification and validation of a retrospective cohort of patients
with type 2 diabetes (T2DM) from four PCORnet sites.
Methods: We adapted existing computable phenotypes (CP) for the identification
of patients with T2DM and evaluated their performance across four PCORnet sites
(2012‐2016). Patients entered the cohort on the earliest date they met one of three
CP categories: (CP1) coded T2DM diagnosis (ICD‐9/ICD‐10) and an antidiabetic pre-
scription, (CP2) diagnosis and glycosylated hemoglobin (HbA1c) ≥6.5%, or (CP3) an
antidiabetic prescription and HbA1c ≥6.5%. We required evidence of health care uti-
lization in each of the 2 prior years for each patient, as we also developed an incident
T2DM CP to identify the subset of patients without documentation of T2DM in the
365 days before t0. Among a systematic sample of patients, we calculated the positive
predictive value (PPV) for the T2DM CP and incident‐T2DM CP using electronic
health record (EHR) review as reference.
Results: The CP identified 50 657 patients with T2DM. The PPV of patients ran-
domly selected for validation was 96.2% (n = 1572; CI:95.1‐97.0) and was consis-
tently high across sites. The PPV for the incident‐T2DM CP was 5.8% (CI:4.5‐7.5).
Conclusions: The T2DM CP accurately and efficiently identified patients with
T2DM across multiple sites that participate in PCORnet, although the incident
T2DM CP requires further study. PCORnet is a valuable data source for future epide-
miological and comparative effectiveness research among patients with T2DM.ipt has not been posted or presented elsewhere and is was funded through a Patient‐Centered Outcomes Research
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diabetes1 | INTRODUCTION
In 2014, the Patient‐Centered Outcomes Research Institute (PCORI)
established a national, distributed research network of intercon-
nected health care data systems integrated under a standardized,
common data model (CDM) known as PCORnet: The National
Patient‐Centered Clinical Research Network.1,2 Similar to the Sentinel
CDM, the PCORnet CDM facilitates the rapid and efficient conduct
of research across approximately 80 sites while allowing sites to
maintain control over their data, thereby reducing patient privacy
and site autonomy concerns.3 PCORnet represents a potentially
transformative data resource, because it remains one of the few that
allows for the inclusion of data derived from the electronic health
record (EHR), including laboratory and clinical data. Nevertheless,
few studies have characterized the use and validity of PCORnet data
to conduct observational studies.
Type 2 diabetes mellitus (T2DM) is a common chronic condition
that represents a major public health concern in the United States
and abroad.4-6 In addition to significantly increasing the risk of cardio-
vascular disease, renal disease, and mortality, T2DM contributes to
rising health care costs.4 There are multiple medications available
for management of T2DM and comparative effectiveness research
to determine the most effective and safe T2DM treatment regimens
for specific groups of patients is a major research priority.7 Large
well‐designed observational studies can help identify the benefits
and harms of specific treatments among patients with T2DM, partic-
ularly among those who may be underrepresented in clinical trials
(ie, the elderly and those with certain comorbidities such as heart
and renal disease).7-9 The identification of patients with T2DM from
EHR and administrative databases has been conducted extensively
in the prior literature.10-23
Most previous studies have identified and studied patients with
T2DM using EHR and administrative databases within well‐defined
but single data systems. However, less is known about the
implementation of those strategies across diverse systems and at a
large scale.10-23 Therefore, T2DM represented an optimal condition
for us to construct, characterize and validate a cohort of patients with
T2DM across four diverse PCORnet sites to determine the utility of
using these integrated data to conduct epidemiological and compara-
tive effectiveness research.2 | METHODS
2.1 | Data sources
PCORnet is a distributed research network of 13 clinical data
research networks (CDRNs) and 20 patient‐powered research net-
works (PPRNs). Each CDRN is composed of one or more sites with
an integrated health care data system that captures the information
on the patient population receiving care within the system
(representing approximately 80 individual sites). Each site is respon-
sible for individual data standardization according to the PCORnet
CDM, governance, security, and patient privacy policies. PPRNs rep-
resent individual networks of patients with a shared clinical condi-
tion with an established agreement to collect and share data
relevant to the condition of interest.1,2 The PCORnet CDM and data
harmonization strategies have been previously reported.1,2,24 In brief,
individual PCORnet sites construct a standardized research dataset
using the same CDM, allowing the same query program to be dis-
tributed and applied to each dataset across the network to attain a
larger number of patients and facilitate multicenter collaborations.
The PCORnet CDM, adapted from the Mini‐Sentinel CDM, outlines
the exact specifications for data organization and representation in
the analytical research dataset created at each site from their avail-
able EHR information.2,3,24
The CDM includes data from the EHR, clinical, billing, pharmacy
prescription, and laboratory information. Data types can include inpa-
tient and outpatient encounters, medication data, laboratory data,
and vital signs. Data may be structured (ICD9 CM/ICD10 codes) or
semi‐structured (laboratory tests and results).25 The CDM uses a
unique study patient identifier to allow integration of different data
types for the generation of analytical datasets while maintaining all
personal identifiers and dates protected within the secured CDM
data structure.2.2 | Constructing a retrospective cohort of patients
with T2DM
Initial development and refinement of the pilot computable phenotype
(CP) occurred at Vanderbilt University Health System (VUHS)
KEY POINTS
• PCORnet (the National Patient‐Centered Clinical
Research Network) is a distributed research network
composed of nearly 80 individual health care sites
integrated under a standardized, common data model.
• Among 1572 patients randomly sampled from a cohort of
50 657 patients identified with type 2 diabetes from four
PCORnet sites, the positive predictive value for the
presence of type 2 diabetes was 96.2% using manual
electronic health record review as the reference.
• PCORnet represents an innovative data source for
future epidemiological and comparative effectiveness
research among patients with T2DM.(additional details in Supplement). We used the final iteration of the
CP from VUHS to identify patients with T2DM across four diverse
PCORnet sites in the southern United States using data from 1
January 2012 through 31 December 2016. The four sites included
VUHS, the University of North Carolina (UNC), the OneFlorida CDRN,
and the Tulane CDRN. The VUHS and UNC sites represent the Mid‐
South CDRN, and each include a large academic medical center with
affiliated community clinics in middle Tennessee and North Carolina,
respectively. The OneFlorida CDRN includes three large university
systems and nine unique clinical systems providing care to 9.7 million
patients. The Tulane CDRN represents a subset of the REACHnet
CDRN that encompasses over 4 million patients across multiple aca-
demic medical centers and health systems in Southeastern Louisiana.
The T2DM CP consisted of three CP categories and were based on
previously validated T2DM CP definitions to identify patients with
T2DM. These CPs were pilot tested at VUHS using EHR review of a
random sample of 60 charts by two physicians using an iterative pro-
cess to achieve consensus on the presence of T2DM.
We identified adult patients at each site on the earliest date (t0)
they met one of the three CP categories for T2DM: (1) A coded inpa-
tient or outpatient T2DM diagnosis (ICD9/ICD10) [eTable 1] and an
antidiabetic medication prescription (eTable 2) within the 90 days fol-
lowing the diagnosis date (CP1); (2) a coded T2DM diagnosis and an
outpatient glycolated hemoglobin (HbA1C) value≥6.5%within 90 days
before or after the diagnosis date (CP2) (laboratory values queried using
Logical Observation Identifiers, Names and Codes (LOINC) codes
(eTable 3); or (3) any antidiabetic medication prescriptionwithin 90 days
before or after an outpatient HbA1C value ≥6.5% (CP3). For each CP
category, t0 for each patient was the earliest date of the two criteria.
If patients met more than one CP on t0, we classified individuals hierar-
chically as CP1, CP2, and CP3, respectively. Eligible patients were
required to have≥1 health care encounter in each of the 2 years before
t0 to assure active use of their respective health care system. Finally, we
excluded patients with coded diagnoses of gestational diabetes, predi-
abetes, and type 1 diabetes or evidence of a positive beta human cho-
rionic gonadotropin test as a marker for pregnancy during the 90 days
before or after t0. Patients were identified with T2DM on the earliest
of all eligible dates during the study period, such that the identification
of an exclusion criterion within 90 days of an eligible t0 might exclude
patient entry on that date but did not preclude the patient from
entering the cohort on a subsequent date when all eligibility criteria
were met. In addition, we classified identified patients as having
incident or new onset diabetes if they fulfilled the incident T2DM
CP definition that required no evidence of T2DM (ie, diagnosis,
medication prescribed, or elevated HbA1c) in the 365 days prior to
t0 within each CDRN. The IRB for each participating site approved
the study protocol.2.3 | Chart review process
To determine the accuracy of the T2DM CP to identify patients with
T2DM within PCORnet sites, we conducted structured chart reviews
in a systematic sample of patients identified using the T2DM CP. We
verified diagnoses, medication use, and HbA1c values identified fromthe query of the site‐specific CDM against the gold standard of infor-
mation in the EHR. To attain a sample with CP distribution propor-
tional to that observed at the site where the CPs were developed
and pilot tested, each site randomly selected 400 patients identified
in the following proportions, 71.5% CP1; 27% CP2; and 1.5% CP3.
At least two trained study personnel conducted the EHR review at
each site after completing a mandatory training session at each site
(details included in Supplement).2.3.1 | Chart reviews
After the training process, for each identified patient in the sample,
we reviewed the EHR for each patient within 180 days (90 days
before and after) of the index date (t0). The review of each individual
record in the EHR was only conducted by a single reviewer at each
site, although each reviewer could flag a record for review and data
abstraction by a designated physician expert at each site. Reviewers
documented evidence within the ascertainment period of T2DM diag-
noses (as well as type 1 diabetes, gestational diabetes, prediabetes,
and diabetes controlled with lifestyle modification) from patient sum-
maries, admission/discharge summaries, and clinic/outpatient visit
summaries. Evidence of antidiabetic medication prescriptions was
identified from prescription information in the EHR, and evidence of
elevated HbA1c values was recorded only from site‐specific HbA1c
laboratory results in the EHR. Evidence of each criteria was
abstracted using a standardized and customized REDCap electronic
data capture instrument.26 Additionally, the clinical reviewers docu-
mented any diagnosis of T2DM in all documentation available in the
EHR during the time period before t0. We assigned study specific
identifiers to each patient at the individual sites so that no identifiable
patient information was recorded in the data capture instrument. The
information in the patients' EHR was considered the gold standard for
all elements assessed. Thus, if there was no information in the EHR
regarding an element of interest, we considered it evidence the
patient did not have the condition, medication prescription, or labora-
tory value.
TABLE 1 Characteristics of patients in the retrospective cohort
identified with T2DM, PCORnet, 2012‐2016; April 2018 PCORnet
Data Query
VUHSa OneFloridab UNCc Tulane
N 13 782 14 881 19 731 2263
Age in years (%)
18‐29 79 (0.6) 103 (0.7) 88 (0.4) 20 (0.9)
30‐39 253 (1.8) 425 (2.9) 392 (2.0) 67 (3.0)
40‐49 1065 (7.7) 1357 (9.1) 1620 (8.2) 202 (8.9)
50‐59 2743 (19.9) 3261 (21.9) 3822 (19.4) 425 (18.8)
60‐69 4272 (31.0) 4762 (32.0) 5728 (29.0) 738 (32.6)
70‐79 3586 (26.0) 3388 (22.8) 5249 (26.6) 548 (24.2)
80‐89 1464 (10.6) 1325 (8.9) 2342 (11.9) 214 (9.5)
90+ 319 (2.3) 243 (1.6) 473 (2.4) 49 (2.2)
Unavailablea Td 17 (0.1) 17 (0.1) 0 (0.0)
Female (%) 6486 (47.1) 8468 (56.9) 10 214 (51.8) 1224 (54.1)
Race (%)2.4 | Statistical analysis
We calculated the positive predictive value (PPV) of the T2DM CP for
identifying adult patients with T2DM in the PCORnet data. Among all
patients identified by the CP, confirmed cases were those patients
with evidence in the medical record within 90 days of t0 of a docu-
mented T2DM diagnosis (including diabetes controlled with lifestyle
modification) and documented antidiabetic medication prescription
(CP1), documented T2DM diagnosis, and documented elevated
HbA1c (CP2) or documented antidiabetic medication prescription
and elevated HbA1c (CP3), and without documented evidence in the
medical record of type 1 diabetes, gestational diabetes, pregnancy,
or prediabetes without evidence of type 2 diabetes within 90 days
of t0. We calculated 95% confidence intervals (CI) for the PPV using
Wilson's formula.27 Secondary analyses assessed the PPV for each
CP category and each site. As a sensitivity analysis, we assessed the
PPV for each CP and each site based on the ICD coding era in which
each patient was identified (all four sites transitioned from ICD9 to
ICD10 in October 2015, althoughTulane allowed ICD9 codes through
May 2016). We further assessed the PPV for the incident or new
onset T2DM CP. All analyses were performed in Stata‐IC, version
15.1 (College Station TX), and manuscript preparation was completed
in part using StatTag (Northwestern University).28Black 2573 (18.7) 5439 (36.5) 5454 (27.6) 1515 (66.9)
Missing 101 (0.7) 96 (0.6) 620 (3.1) 52 (2.3)
Other 351 (2.5) 1114 (7.5) 1201 (6.1) 78 (3.4)
White 10 756 (78.0) 8232 (55.3) 12 446 (63.1) 618 (27.3)
CP type (%)
CP1 9870 (71.6) 12 302 (82.7) 12 803 (64.9) 1470 (65.0)
CP2 3698 (26.8) 2460 (16.5) 6900 (35.0) 783 (34.6)
CP3 214 (1.6) 119 (0.8) 28 (0.1) 10 (0.4)
aVanderbilt University Health System.
bOneFlorida CDRN.
cUniversity of North Carolina.
dPCORnet low threshold masking.3 | RESULTS
3.1 | Cohort assembly and sample characteristics
Using theT2DM CP, we initially identified 205 004 patients ≥18 years
of age with possible T2DM among 4 696 145 patients across the four
sites. The final retrospective cohort from which the validation sample
was identified comprised 51 226 patients with T2DM (Figure 1). After
the validation sample was identified and data collected in January
2018, a regularly scheduled process to refresh the PCORnet dataFIGURE 1 Patients withT2DM identified from four PCORnet sites (2012
data model; 3OneF: One Florida; 4UNC: University of North Carolina; 5T2structure incorporated additional health care encounter information
at each site, resulting in minor changes to the underlying T2DM
cohorts at each site from which descriptive statistics were derived
(n = 50 657) (Table 1). Patients with T2DM were primarily ≥60 years‐2016). 1VUHS: Vanderbilt University Health System; 2CDM: Common
DM: Type 2 diabetes mellitus
of age (68.5%), female (52.1%), and White (63.3%), although popula-
tion characteristics varied by site (Table 1).TABLE 3 Random sample of patients with possible incident T2DM
by computable phenotype (CP) and site among selected health care




Confirmed PPVa (95% CIb)




573 38 6.6 (4.9, 9.0)
CP2—diabetes diagnosis
and HbA1c ≥6.5%
332 13 3.9 (2.3, 6.6)
CP3—HbA1c ≥6.5%
and medication use




199 6 3.0 (1.4, 6.4)
OneFlorida 213 20 9.4 (6.2, 14.1)
University of North Carolina 307 20 6.5 (4.3, 9.8)
Tulane 197 7 3.6 (1.7, 7.2)
aPPV: positive predictive value.
bConfidence interval using Wilson's formula.3.2 | Positive predictive value of CP
Each site systematically selected a random sample of 400 patients
identified using theT2DM CP for review. We completed EHR abstrac-
tion for 98.3% (n = 1572) of the selected sample (>96% for each site)
as 26 records across all sites were unavailable for review and two
records were incomplete in data abstraction.
Of the 1572 patients identified and reviewed, 1512 [PPV: 96.2%
(CI: 95.1‐97.0)] had confirmed T2DM (Table 2). Interestingly, a small
percentage of patients identified using the T2DM CP had evidence
of type 1 diabetes, gestational diabetes, or prediabetes (0.5%), even
though theT2DM CP excluded individuals with evidence of these con-
ditions. The PPV was highest for CP1 [PPV: 96.4% (CI: 95.2‐97.4)],
high for CP2 [PPV: 96.1% (CI: 93.8‐97.5)], and moderate for CP3
[PPV: 81.3% (CI: 57.0‐93.4)], albeit there were a small number of
patients identified using CP3. The overall PPV was >95.0% across all
four sites (Table 2).
Of patients identified with T2DM using CP1, 63.1% also had an
HbA1c value ≥6.5% within 180 days of t0, which was not a required
element of CP1. Similarly, 49.8% of patients identified using CP2 had
evidence of an antidiabetic medication prescription and 75.0% of
patients identified using CP3 had evidence of aT2DM diagnosis within
180 days of t0 (eTable 4). Among the 60 patients (3.8% of total) that
were not confirmed by EHR review, most patients identified using
CP1 (n = 40) lacked evidence of an antidiabetic medication prescription
only (85.0%), while those identified using CP2 primarily lacked evidence
of an elevated HbA1c (47.1%). Only three patients identified using CP3
did not have confirmed T2DM, either due to the lack of an antidiabetic






Overall 1572 1512 96.2
By computable phenotype
CP1—diabetes diagnosis and medication use 1124 1084 96.4
CP2—diabetes diagnosis and HbA1c ≥6.5% 432 415 96.1
CP3—HbA1c ≥6.5% and medication use 16 13 81.3
By site
Vanderbilt University Health System 398 379 95.2
OneFlorida 391 382 97.7
University of North Carolina 396 380 96.0
Tulane 387 371 95.9
aPPV: positive predictive value.
bConfidence interval using Wilson's formula.
cCriteria included evidence of a diabetes diagnosis, diabetes medication use, orOf the total 1572 charts reviewed, there were 916 (58.2%)
patients identified as incident or new‐onset T2DM. Among them, 53
[PPV: 5.8% (CI: 4.5‐7.5)] were true new onset or incident T2DM after
EHR review (Table 3). The incident T2DM CP performed poorly for all
T2DM CP categories (PPV range: 3.9‐18.2) and across all four sites
(PPV range: 3.0‐9.4) (Table 3). In the sensitivity analysis by ICD coding
era, the PPV was similar among patients identified in the ICD9 era ver-
sus the ICD10 era [PPV: 96.5 (CI: 95.2‐97.5) and PPV: 95.6 (CI: 93.4‐
97.1), respectively] [eTable 5]. The results were similar across ICD cod-
ing eras for CP1 and CP2, as well as for each site [eTable 5].phenotype (CP) and site at selected health care systems in PCORnet,
firmed T2DM (n = 1512) Patients without Confirmed T2DM (n = 60)
a (95% CIb)





(95.1, 97.0) 52 8
(95.2, 97.4) 37 3
(93.8, 97.5) 13 4
(57.0, 93.4) 2 1
(92.7, 96.9) 18 1
(95.7, 98.8) 8 1
(93.5, 97.5) 15 1
(93.4, 97.4) 11 5
elevated HbA1c ≥6.5%.
4 | DISCUSSION
PCORnet is a large integrated data resource with potential for the
conduct of clinical trial, epidemiological and comparative effective-
ness research, yet the performance of systematic strategies to iden-
tify patients with common conditions such as T2DM in PCORnet has
not been previously characterized. We identified a large number of
patients with T2DM CP (n = 50 657) across four PCORnet sites
(representing only around 5% of PCORnet sites). The vast majority
of identified cohort members were confirmed to have T2DM, with
an overall PPV of 96.2%. The PPVs were consistently high for all
CP categories that were defined by combinations of T2DM diagno-
ses, antidiabetic medication prescriptions and elevated HbA1c labo-
ratory values and across all four sites representing different EHR
systems, patient populations, and geographical regions with a high
prevalence of T2DM. In contrast, the incident T2DM CP incorrectly
identified many prevalent T2DM cases as incident or new onset, an
important consideration for future observational studies using
PCORnet.
Strategies for the identification of patients withT2DM from a sin-
gle hospital or within a single network‐based EHR system have been
reported and applied extensively, although prior studies used different
inclusion and exclusion criteria to identify patients withT2DM.10-23 Of
those that applied specific algorithms requiring multiple sources of
evidence to identify patients withT2DM (ie, >1 of either a coded diag-
nosis, prescribed antidiabetic medications or elevated laboratory
values; in addition to evidence of baseline enrollment and health care
utilization), the study populations ranged in size from 10 000 to
500 000 patients.10-23 Distinct from our study, several of these prior
studies centered only on a single health care system13-16 or used
coded diagnoses, antidiabetic medication use, and laboratory values
to identify patients with T2DM from de‐identified, commercially avail-
able databases, which could not be validated against patients' EHR
information.17-21 In contrast, we identified 50 657 patients with
T2DM in only four of about 80 PCORnet sites using CP definitions
of coded diagnoses, prescribed antidiabetic medications, and labora-
tory values similar to the Mini‐Sentinel recommendations for identify-
ing patients with T2DM.22,23 Our study demonstrates the successful
implementation of those strategies in PCORnet and highlights the
scalability of the process to enable the identification of patients with
T2DM for the conduct of retrospective and prospective cohort studies
as well as pragmatic clinical trials.
The PPV of our T2DM CP was similar or higher than other prior
studies that sought to identify patients with T2DM. In a prior study
of 18 131 patients with clinically confirmed T2DM in two California
counties, using an HbA1c ≥6.5% to identify patients with T2DM at
any time during the 5‐year study period had a high PPV (83.2%).29
In another prior study among 101 278 children <20 years of age from
two health care systems in North and South Carolina, multiple algo-
rithms requiring evidence of ≥2 diagnosis codes (or the ratio of
T2DM codes to type 1 diabetes codes) had low to moderate PPV
(highest 75.5%) compared with manual chart review.30 In a separate
study conducted at a single ambulatory practice, a two‐step definition
that first identified all patients with evidence of diabetes based on
diagnosis codes, laboratory values, and antidiabetic medications andfurther differentiated patients with T2DM from type 1 diabetes based
on oral hypoglycemic use had a PPV around 90.0% for identifying
patients with T2DM relative to manual EHR review.31 Furthermore,
a comprehensive study involving the application of 8 EHR‐T2DM phe-
notypes to a large sample of 173 503 patients reported a varied sen-
sitivity across definitions, but a consistently high specificity for each
definition (95%‐99%).12 In comparison, our approach had a PPV of
96.2% among a large sample of cases in PCORnet (likely approximat-
ing a high specificity for identifying T2DM cases), providing evidence
that patients with T2DM can be successfully and accurately identified
in PCORnet.
We purposefully used a T2DM CP that required baseline health
care utilization among identified members of our retrospective cohort
to attempt to identify patients with incident T2DM. Although identify-
ing the true date of T2DM disease onset is challenging even in purely
clinical settings, it would be advantageous to be able to do so in the
design of comparative effectiveness studies and to allow the charac-
terization of the evolution of disease and management over time.32
Nevertheless, upon EHR review, many of the patients identified using
the incident T2DM CP were prevalent T2DM patients receiving diabe-
tes treatment outside the health care system who had transitioned to
receive their diabetes care within the network. In addition, the inci-
dent T2DM CP incorrectly identified patients with prevalent T2DM
receiving regular non‐diabetes care, imaging, or surgical procedures
at each site as having incident or new‐onset T2DM. Consequently,
the performance of our CP for identification of incident T2DM was
very poor. As noted in prior research, identification of patients with
T2DM within large health care systems does not always indicate that
such systems are the primary or initial site of diabetes management.33
As outlined in a recent study, requiring at least one encounter coded
as primary care or endocrinological/diabetes in each of the prior
2 years might better differentiate incident or new onset T2DM from
patients with prevalent T2DM.13,34 The identification of patients with
incident T2DM in EHR data remains challenging, and so additional
studies are needed to determine the performance of incident T2DM
definitions in PCORnet.
An important limitation of our study was the inability to deter-
mine the sensitivity and specificity of the T2DM CP in PCORnet. To
calculate sensitivity and specificity, we would have needed to review
records for patients that were not identified using the T2DM CP.
Although we did not calculate specificity directly, the estimated prev-
alence of diagnosed diabetes in the adult population nationally and in
PCORnet is approximately 10%, and therefore our high PPV likely
approximates a high specificity.35 The high PPV of the T2DM CP sug-
gests these definitions can be used to identify patients withT2DM for
future observational or pragmatic clinical studies using PCORnet
data.35-37
Similar to other observational studies which utilize EHR or claims
data, missing or incomplete diagnosis, laboratory, or medication pre-
scribing information could have limited our ability to identify or con-
firm patients with T2DM in the study (although the impact on the
observed PPV would be minimal). Another important consideration
for the use of PCORnet to study patients with T2DM is that we did
not assess whether each site was the sole source of treatment and
care, which could have implications for the conduct of longitudinal
studies and for the demonstration of history of T2DM. Although most
observational studies involving patients with T2DM use pharmacy
information on filled medication prescriptions, we instead used pre-
scribing information from the EHR to identify and characterize medi-
cation use. Future work is needed to determine the accuracy of the
prescribing information in relation to actual medication dispensing
and use in PCORnet.
In conclusion, our study demonstrates the successful implementa-
tion of a strategy to accurately identify a large cohort of patients with
T2DMwithin PCORnet, although additional study is needed to identify
patients with new‐onset or incident T2DM. PCORnet represents a
novel data platform for the identification of patients with chronic dis-
ease and the efficient conduct of clinical and epidemiological research.
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